Beta-adrenergic receptors (β1 predominantly in the heart; β2 in bronchi and peripheral vasculature) couple via Gs proteins to adenylyl cyclase, increasing cyclic AMP and activating protein kinase A (PKA). PKA phosphorylates multiple cardiac ion channels, producing the familiar sympathetic response: increased heart rate, AV nodal conduction velocity, and contractility.1
Beta-blockers competitively antagonize catecholamine binding at β-adrenergic receptors, reversing these effects. Their antiarrhythmic actions operate through four distinct mechanisms:1,2
PKA phosphorylation of hyperpolarization-activated cyclic nucleotide-gated channel 4 (HCN4) channels increases If amplitude and shifts its activation curve to more positive voltages, steepening the slope of spontaneous phase 4 depolarization in SA nodal and Purkinje cells. Beta-blockers reverse this shift, reducing the intrinsic firing rate of the SA node and suppressing abnormal automaticity in subsidiary pacemakers. This is the primary mechanism of beta-blocker efficacy in inappropriate sinus tachycardia and exercise-induced ventricular arrhythmias.1
Sympathetic tone accelerates AV nodal conduction by increasing ICaL (via PKA phosphorylation of Cav1.2) and If in nodal cells. Beta-blockers attenuate both, prolonging AV nodal effective refractory period and slowing conduction velocity. On ECG, this manifests as PR interval prolongation. This mechanism underlies beta-blocker efficacy for ventricular rate control in atrial fibrillation and flutter, and for terminating AV nodal re-entrant circuits where the AV node is a required limb.2
Catecholamine excess drives intracellular Ca2+ overload via PKA-mediated phosphorylation of L-type Ca2+ channels and phospholamban (increasing SR Ca2+ load), and RyR2 phosphorylation (increasing SR Ca2+ leak). This generates delayed afterdepolarizations (DADs) via NCX activation. Beta-blockers interrupt this cascade, making them uniquely effective in arrhythmias driven by DAD-mediated triggered activity: catecholaminergic polymorphic VT (CPVT), exercise-induced VT, and arrhythmias complicating myocarditis or pheochromocytoma.3
Beta-blockers reduce myocardial oxygen demand (via decreased heart rate and contractility), improve subendocardial perfusion (by prolonging diastole), and attenuate ischemia-induced heterogeneity of repolarization. These effects collectively reduce the substrate for re-entrant ventricular arrhythmias in the setting of coronary artery disease, accounting for the mortality benefit demonstrated in multiple post-MI trials.4
Beta-blockers differ in receptor selectivity (β1-selective vs. non-selective), lipophilicity (determining CNS penetration and hepatic vs. renal clearance), intrinsic sympathomimetic activity (ISA), and ancillary properties. These differences have direct clinical implications for agent selection in arrhythmia management.2 Metoprolol (tartrate and succinate) is β1-selective and moderately lipophilic. The tartrate form has a half-life of 3 to 7 hours; the extended-release succinate formulation achieves approximately 24-hour coverage and is the guideline-preferred form for HFrEF. Both are hepatically metabolized via CYP2D6 (cytochrome P450 2D6). Esmolol is β1-selective with a half-life of approximately 9 minutes via red blood cell esterase hydrolysis; IV only, ideal for perioperative and ICU titration. Propranolol is non-selective (β1+β2) and highly lipophilic with a half-life of 3 to 6 hours, hepatic metabolism via CYP2D6 and CYP1A2, and significant CNS penetration; preferred in thyrotoxicosis-related arrhythmias. Carvedilol is non-selective with additional α1-blockade, moderate-to-high lipophilicity, a half-life of 6 to 10 hours, and hepatic metabolism via CYP2D6 and CYP2C9 (cytochrome P450 2C9); confers mortality benefit in HFrEF. Nadolol is non-selective (β1+β2) and hydrophilic with a half-life of 14 to 24 hours and renal elimination; preferred in CPVT and LQTS for its consistent pharmacokinetics. Atenolol is β1-selective, hydrophilic, half-life 6 to 9 hours, renally eliminated; dose reduction required in CKD, used in LQT syndrome type 1.
Metoprolol tartrate (immediate-release) and succinate (extended-release) are the most commonly used agents for cardiac arrhythmia management. IV metoprolol tartrate (2.5–5 mg IV bolus, up to 3 doses at 5-minute intervals) achieves rapid AV nodal slowing for rate control in AF/AFL. Metoprolol is a CYP2D6 substrate; poor metabolizers achieve 3–5-fold higher plasma levels, increasing the risk of bradycardia and hypotension.2
Esmolol's 9-minute half-life results from rapid hydrolysis by red blood cell esterases, entirely independent of hepatic or renal function. This makes it uniquely suitable for settings requiring precise, rapidly reversible β1-blockade: perioperative tachyarrhythmias, thyroid storm, aortic dissection, and ICU rate control where hemodynamic tolerance is uncertain. Standard dosing: loading dose 500 mcg/kg IV over 1 minute, followed by infusion at 50–300 mcg/kg/min. Effects dissipate within 20–30 minutes of discontinuation.2
Propranolol is non-selective (β1 + β2) and highly lipophilic, producing prominent CNS effects (fatigue, depression, vivid dreams) and significant first-pass hepatic metabolism (bioavailability ~25–40%). Its membrane-stabilizing property (weak Class I Na+ channel blockade) is pharmacologically demonstrable but clinically relevant only at very high doses. Propranolol is the preferred agent in thyrotoxicosis-related arrhythmias (blocking peripheral T4→T3 conversion via β2-mediated deiodinase inhibition) and is used in portal hypertension for variceal prophylaxis, indications where non-selectivity is advantageous.
Nadolol is the preferred beta-blocker in both CPVT and LQTS because its long half-life (14–24 hours) and renal elimination (without hepatic metabolism) provide consistent, predictable plasma levels, minimizing the troughs that could permit breakthrough catecholamine-driven arrhythmias. It is hydrophilic and has low CNS penetration. Dose reduction is essential in chronic kidney disease.5
Beta-blockers are first-line agents for ventricular rate control in AF, particularly in patients with heart failure with reduced ejection fraction (HFrEF) and those with sympathetically driven tachycardia (exercise, thyrotoxicosis, post-surgical AF). The 2023 ACC/AHA/ACCP/HRS AF guideline (where ACCP = American College of Clinical Pharmacy) recommends a resting rate target of <110 bpm as initial rate control, with tighter control (<80 bpm) for symptomatic patients.5 In AF with rapid ventricular response in the hemodynamically stable patient, IV metoprolol or IV esmolol achieves rate control within minutes. Beta-blockers are preferred over digoxin for rate control during exercise, as digoxin's vagotonic mechanism is ineffective during sympathetic activation. In patients with decompensated HFrEF, cautious low-dose IV metoprolol remains appropriate with careful hemodynamic monitoring; non-DHP CCBs are avoided in HFrEF due to negative inotropy.5
For AVNRT and atrioventricular reentrant tachycardia (AVRT), beta-blockers serve as both acute and chronic management options. IV metoprolol or esmolol can terminate AV nodal-dependent re-entrant tachycardias by blocking the slow pathway or the retrograde limb of the circuit. For long-term prophylaxis of SVT in patients declining or not eligible for ablation, oral metoprolol or atenolol are first-line. Beta-blockers are less effective than CCBs for acute termination of AVNRT (adenosine remains first-line) but are preferred for chronic suppression when CCBs are contraindicated or poorly tolerated.2
Multiple large trials (BHAT, CAPRICORN, MERIT-HF) established beta-blockers as standard of care post-MI, with relative risk reductions in sudden cardiac death of 30–50%.4 The mechanism is multifactorial: suppression of catecholamine-driven triggered activity, reduction of ischemic substrate, and β1-blockade preventing the increases in dV/dt and Ca2+ entry that predispose to VF. Carvedilol and metoprolol succinate are guideline-preferred agents in post-MI patients with LV dysfunction.
CPVT is caused by gain-of-function mutations in RyR2 (type 1, autosomal dominant) or loss-of-function mutations in calsequestrin-2 (type 2, autosomal recessive), resulting in pathologic SR Ca2+ leak during adrenergic stimulation. Catecholamines trigger bidirectional or polymorphic VT that characteristically terminates at rest and recurs with exercise or emotional stress.5 Beta-blockers are the cornerstone of CPVT therapy. Nadolol (1–2 mg/kg/day) is preferred over selective agents due to its β2-blockade (reducing catecholamine-mediated RyR2 phosphorylation via both receptor subtypes) and consistent pharmacokinetics. Despite optimal beta-blockade, up to 30% of patients have breakthrough events; flecainide (low-dose, targeting RyR2 directly) or ICD implantation is added in refractory cases. Beta-blockers should never be abruptly discontinued in CPVT — withdrawal precipitates VF.5
In LQT1 (loss-of-function KCNQ1 mutations reducing slow delayed rectifier potassium current (IKs)), the QT-rate adaptation to exercise is impaired, and arrhythmias are characteristically triggered by sympathetic activation (swimming, sudden exertion). Beta-blockers are highly effective in LQT1, reducing event rates by ~50–70% in symptomatic patients.8 Nadolol or atenolol (for their consistent half-lives) are preferred. In LQT2 (hERG/KCNH2 mutations reducing rapid delayed rectifier potassium current (IKr)), arrhythmias are triggered by auditory stimuli and arousal; beta-blockers are moderately effective but less so than in LQT1. In LQT3 (SCN5A gain-of-function increasing late sodium current (INaL)), beta-blockers have limited efficacy and mexiletine is typically added.
Perioperative AF is the most common complication of cardiac surgery, occurring in 25–40% of patients. Prophylactic beta-blockade (continuing pre-operative therapy or initiating metoprolol perioperatively) is the primary pharmacologic prevention strategy. In the ICU, IV esmolol is the preferred agent for hemodynamically significant tachyarrhythmias where rapid titration and reversibility are required. In sepsis-related AF with rapid ventricular response, esmolol infusion has been associated with reduced mortality in small trials, though this remains investigational.2
Bradycardia and AV block: The most clinically significant cardiac adverse effect. Monitor heart rate and PR interval; hold if HR <50 bpm at rest or if PR >0.28 s. Hypotension: More pronounced with non-selective agents and at initiation. Reduce dose in hypovolemia and HFrEF decompensation.
Bronchospasm: Mediated by β2-blockade impairing bronchodilation. Use β1-selective agents (metoprolol, atenolol, bisoprolol) in reactive airway disease; non-selective agents are contraindicated in severe asthma. Fatigue and exercise intolerance: Common; related to both β1-blockade and reduced cardiac output reserve. CNS effects: Lipophilic agents (propranolol, metoprolol) cross the blood-brain barrier; fatigue, depression, sleep disturbance, and vivid dreams. Use hydrophilic agents (nadolol, atenolol) if CNS effects are problematic. Metabolic: Mask hypoglycemic symptoms in insulin-dependent diabetes (non-selective agents more so); blunt compensatory tachycardia. Use β1-selective agents in insulin-dependent diabetics. Peripheral vasoconstriction: Non-selective agents exacerbate Raynaud's phenomenon and peripheral vascular disease. β1-selective or vasodilatory agents (carvedilol, labetalol) are preferred.
Key Contraindications to Beta-Blockers in Arrhythmia Management
Decompensated heart failure (acute pulmonary edema), initiate only after stabilization Cardiogenic shock High-degree AV block (2nd or 3rd degree) without a functioning pacemaker Sick sinus syndrome without pacemaker backup Severe reactive airway disease (non-selective agents) / symptomatic bronchospastic asthma Cocaine-induced tachycardia, unopposed α-stimulation worsens coronary vasospasm Acute decompensated COPD with bronchospasm
Abrupt discontinuation of beta-blockers, particularly after long-term high-dose therapy, causes upregulation of β-adrenergic receptor density (a compensatory response to chronic blockade). Sudden removal of blockade exposes this supersensitive receptor population to endogenous catecholamines, producing rebound tachycardia, hypertension, angina, and potentially VF in patients with underlying coronary artery disease. This risk is highest within the first 24–48 hours after abrupt discontinuation.5 Clinical Warning: Beta-Blocker Withdrawal
Never abruptly discontinue beta-blockers in patients with CAD, post-MI LV dysfunction, CPVT, or LQTS. Taper over 1–2 weeks. Pre-operative: continue beta-blockers perioperatively in patients on chronic therapy. Abrupt withdrawal on admission is a preventable cause of perioperative arrhythmia. If withdrawal is unavoidable (surgery, side effects), bridge with esmolol IV if arrhythmia risk is high.
Beta-blockers paradoxically improve outcomes in HFrEF despite their negative inotropic properties. The mechanism is chronic neurohormonal modulation: sustained sympathetic activation in heart failure is maladaptive, causing β-receptor downregulation, myocyte apoptosis, and adverse remodeling. Long-term beta-blockade (carvedilol, metoprolol succinate, bisoprolol) reverses remodeling, increases EF, and reduces sudden cardiac death by 34–44% in large trials (COPERNICUS, MERIT-HF, CIBIS-II).5 The critical clinical rule: initiate beta-blockers only when HFrEF is clinically compensated (euvolemic). Starting in decompensated heart failure causes acute hemodynamic deterioration. Begin at the lowest dose (e.g., carvedilol 3.125 mg BD, metoprolol succinate 12.5–25 mg OD) and uptitrate over weeks to months to the maximally tolerated dose. Patients already on beta-blockers who decompensate should have the dose halved rather than stopped entirely.5
The mortality benefit of beta-blockers in post-MI patients and in heart failure with reduced ejection fraction is among the most robust findings in cardiovascular pharmacology. The following trial summaries provide the quantitative foundation needed when weighing beta-blocker selection, dose targets, and the decision to escalate versus substitute therapy in these populations.
The Beta-Blocker Heart Attack Trial (BHAT, 1982) randomized 3,837 post-MI patients to propranolol (average dose 180 mg/day) or placebo and was stopped early due to a significant reduction in total mortality in the propranolol arm (7.2% vs. 9.8%; relative risk reduction approximately 26%). Sudden cardiac death was reduced by 28%. BHAT established that non-selective beta-blockade post-MI reduces arrhythmic mortality through suppression of catecholamine-driven triggered activity and attenuation of the ischemic arrhythmia substrate.4
The CAPRICORN trial (2001) randomized 1,959 patients with acute MI complicated by LV dysfunction (ejection fraction 40% or less) to carvedilol or placebo, all on background ACE inhibitor therapy. Carvedilol significantly reduced all-cause mortality (12% vs. 15%; hazard ratio 0.77; 95% CI 0.60 to 0.98) and recurrent non-fatal MI. CAPRICORN enrolled patients with overt LV dysfunction, a population previously considered high-risk for beta-blocker initiation, demonstrating that carvedilol is safe and beneficial even in significantly impaired ventricles when initiated carefully in the post-MI stabilization period.4
The MERIT-HF trial (1999) randomized 3,991 patients with stable HFrEF (ejection fraction 40% or less, NYHA Class II through IV) to metoprolol succinate CR/XL or placebo. The trial was stopped early due to a significant reduction in all-cause mortality in the metoprolol group (relative risk reduction 34%; absolute risk reduction 3.8% per year). Sudden cardiac death was reduced by 41%. This is the primary evidence base for metoprolol succinate as a guideline-preferred agent in HFrEF.5
Three large trials established beta-blockers as the pharmacologic cornerstone of HFrEF management and defined the specific agents with proven survival benefit. The class effect cannot be assumed: only carvedilol, metoprolol succinate, and bisoprolol have demonstrated mortality benefit in large randomized trials.
COPERNICUS (2001) randomized 2,289 patients with severe HFrEF (ejection fraction below 25%, NYHA Class III through IV at rest or on minimal exertion) to carvedilol or placebo. Carvedilol reduced all-cause mortality by 35% (relative risk 0.65; 95% CI 0.52 to 0.81) and was associated with fewer hospitalizations. The COPERNICUS population was distinctly high-risk, average ejection fraction 20%, symptoms at rest, making this the definitive evidence that beta-blocker benefit extends to advanced, severe HFrEF, not only mild-to-moderate disease.5
CIBIS-II (1999) randomized 2,647 patients with symptomatic HFrEF (ejection fraction 35% or less, NYHA Class III through IV) to bisoprolol or placebo. The trial was stopped early due to a significant reduction in all-cause mortality (11.8% vs. 17.3%; hazard ratio 0.66; 95% CI 0.54 to 0.81). Sudden death was reduced by 44%. Bisoprolol's high beta-1 selectivity and renal elimination without significant hepatic metabolism make it pharmacokinetically predictable and particularly suitable in patients with hepatic impairment.
The practical implication of this trial evidence is that the choice of beta-blocker in HFrEF is not interchangeable. Only carvedilol, metoprolol succinate, and bisoprolol should be used in HFrEF. Short-acting metoprolol tartrate, atenolol, propranolol, and other agents do not carry proven mortality benefit in this indication and should not be substituted. When a patient on any other beta-blocker is admitted with new HFrEF, conversion to one of the three proven agents is a standard quality measure.
Thyroid storm is an endocrine emergency characterized by extreme sympathetic activation from massive thyroid hormone release. The resulting arrhythmias, including sinus tachycardia, atrial fibrillation, and occasionally ventricular tachycardia, are driven by catecholamine hypersensitivity rather than intrinsic cardiac disease. Beta-blockade is a cornerstone of thyroid storm management for three distinct pharmacologic reasons.
First, beta-blockade directly attenuates the adrenergic manifestations of thyroid storm: tachycardia, hypertension, tremor, agitation, and diaphoresis respond within minutes of IV beta-blocker administration. Second, and uniquely among antiarrhythmic uses, propranolol additionally blocks peripheral conversion of thyroxine (T4) to the more biologically active triiodothyronine (T3) by inhibiting the deiodinase enzyme responsible for this conversion, an effect mediated through beta-2 receptor blockade in peripheral tissues. This mechanism reduces the acute hormonal burden independently of sympathetic blockade.5 Third, ventricular rate control in thyroid storm-associated AF is more effectively achieved with beta-blockers than with digoxin or diltiazem, because the tachycardia is driven by sympathetic excess that overwhelms vagotonic rate control.
Propranolol is the preferred agent in thyroid storm specifically because of its T4-to-T3 conversion blockade in addition to its non-selective beta-blockade. IV propranolol (0.5 to 1 mg IV over 10 minutes, titrated to effect) is used acutely; oral propranolol 60 to 80 mg every 4 to 6 hours is used for sustained management. In patients with reactive airway disease where propranolol is contraindicated, high-dose esmolol infusion provides titratable beta-1 selective rate control without the hormonal conversion benefit but with greater hemodynamic flexibility. Alternatively, diltiazem can be used for rate control if all beta-blockers are contraindicated, though it lacks the T4-to-T3 conversion mechanism.
The perioperative context represents one of the most nuanced areas of beta-blocker prescribing, where the benefit-risk ratio is acutely sensitive to patient selection and timing of initiation. Perioperative atrial fibrillation occurs in 25 to 40% of patients undergoing cardiac surgery and 10 to 20% of those undergoing major non-cardiac surgery. Continuing established beta-blocker therapy perioperatively is unambiguous standard of care: abrupt withdrawal substantially increases arrhythmic risk through beta-receptor upregulation, as discussed in Section 4.3.
The POISE trial (2008) randomized 8,351 patients undergoing non-cardiac surgery to extended-release metoprolol succinate (100 mg starting 2 to 4 hours before surgery, then 200 mg within 6 hours postoperatively) or placebo. Metoprolol significantly reduced the incidence of AF and myocardial infarction but significantly increased 30-day mortality (3.1% vs. 2.3%; hazard ratio 1.33). The excess mortality was attributable to an increase in stroke (1.0% vs. 0.5%) and hypotension-related deaths in the high-dose initiation arm.
The POISE lesson is not that perioperative beta-blockade is harmful, but that high-dose initiation immediately before non-cardiac surgery in beta-blocker-naive patients causes excess harm through hypotension and stroke. Current ACC/AHA perioperative guidelines recommend: continuing beta-blockers in patients already taking them; initiating beta-blockers at least one week before elective surgery in appropriate high-risk patients at low doses with careful titration; and never initiating high-dose beta-blockers on the day of surgery in beta-blocker-naive patients. IV esmolol remains the preferred agent for managing acute intraoperative or postoperative tachyarrhythmias in patients who are not chronically beta-blocked, due to its rapid reversibility.2
Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415(6868):198–205
doi:10.1038/415198aFrishman WH. Beta-adrenergic blockers: a 50-year historical perspective. Am J Ther. 2008;15(6):565–576
doi:10.1097/MJT.0b013e31817a1fd3Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103(2):196–200
doi:10.1161/01.CIR.103.2.196Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–371
doi:10.1016/S0033-0620(85)80003-7Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10(12):1932–1963
doi:10.1016/j.hrthm.2013.05.014Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. J Am Coll Cardiol. 2024;83(1):109–279
doi:10.1016/j.jacc.2023.08.017Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793–2867
doi:10.1093/eurheartj/ehv316Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA. 1990;263(12):1653–1657
doi:10.1001/jama.1990.03440120075031Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–1658
doi:10.1056/NEJM200105313442201